Connor Clark & Lunn Investment Management Ltd. cut its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 51.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 125,341 shares of the medical device company’s stock after selling 133,742 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.19% of Tandem Diabetes Care worth $2,603,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of the business. BlackRock Inc. boosted its holdings in Tandem Diabetes Care by 45.1% in the 1st quarter. BlackRock Inc. now owns 9,207,560 shares of the medical device company’s stock worth $373,919,000 after buying an additional 2,861,120 shares during the last quarter. Paradice Investment Management LLC acquired a new position in shares of Tandem Diabetes Care during the 2nd quarter worth approximately $30,106,000. Jennison Associates LLC boosted its holdings in shares of Tandem Diabetes Care by 252.6% during the 3rd quarter. Jennison Associates LLC now owns 1,122,915 shares of the medical device company’s stock worth $23,323,000 after purchasing an additional 804,488 shares during the last quarter. Chicago Capital LLC boosted its holdings in shares of Tandem Diabetes Care by 699.8% during the 3rd quarter. Chicago Capital LLC now owns 904,410 shares of the medical device company’s stock worth $18,785,000 after purchasing an additional 791,336 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Tandem Diabetes Care during the 2nd quarter valued at approximately $16,127,000.
Tandem Diabetes Care Stock Performance
Tandem Diabetes Care stock opened at $27.34 on Wednesday. Tandem Diabetes Care, Inc. has a twelve month low of $13.82 and a twelve month high of $44.85. The stock’s fifty day simple moving average is $25.80 and its 200-day simple moving average is $23.14. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on TNDM
Tandem Diabetes Care Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Recommended Stories
- Five stocks we like better than Tandem Diabetes Care
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Workday Stock Price is Working on a Buy-the-Dip Opportunity
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 wealth-compounding stocks to beat the market this decade
- What is an Earnings Surprise?
- Palantir Stock Has It all… Except the Analysts’ Support
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.